Lb Pharmaceuticals (LBRX) Enterprise Value (2024 - 2026)

Lb Pharmaceuticals has reported Enterprise Value for 3 years, with the latest figure at -$365.6 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value changed N/A year-over-year to -$365.6 million; the trailing twelve-month figure through Mar 2026 stood at -$365.6 million (changed N/A YoY), and the FY2025 full-year result was -$295.2 million, down 954.37% from the prior year.
• Enterprise Value for Q1 2026 stood at -$365.6 million, down from -$295.2 million in the prior quarter.
• The five-year high for Enterprise Value was -$28.0 million in Q4 2024, with the low at -$365.6 million in Q1 2026.
• Average Enterprise Value over 3 years is -$250.8 million, with a median of -$304.8 million recorded in 2025.
• Peak annual rise in Enterprise Value reached 954.37% in 2025, while the deepest fall reached 954.37% in 2025.
• Tracing LBRX's Enterprise Value over 3 years: stood at -$28.0 million in 2024, then plunged by 954.37% to -$295.2 million in 2025, then fell by 23.85% to -$365.6 million in 2026.
• The last three Enterprise Value figures came in at -$365.6 million (Q1 2026), -$295.2 million (Q4 2025), and -$314.5 million (Q3 2025), per Business Quant data.

Peer Comparison